Evidence map›Paper›PMID 30548288›Full record

ArticleJournal of cellular biochemistry2019

Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature.

Diana L Gerrard, Yao Wang, Malaina Gaddis, Yufan Zhou, Junbai Wang, Heather Witt, Shili Lin, Peggy J Farnham, Victor X Jin, Seth E Frietze

Abstract read
In one paragraph

Article in Journal of cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Diana L GerrardBiomedical Health Sciences Department, University of Vermont, Burlington, VT, USA.
Yao WangDepartment of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
Malaina GaddisDepartment of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Yufan ZhouDepartment of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
Junbai WangDepartment of Pathology, Oslo University Hospital - Norwegian Radium Hospital, Oslo, Norway.
Heather WittDepartment of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Shili LinStatistics Department, The Ohio State University, Columbus, OH, USA.
Peggy J FarnhamDepartment of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Victor X JinDepartment of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX, USA.
Seth E FrietzeBiomedical Health Sciences Department, University of Vermont, Burlington, VT, USA.ORCID 0000-0003-4058-3661
The University of Texas Health Science Center at San Antonio · USUniversity of Southern California · USUniversity of Vermont · USOslo University Hospital · NOThe Ohio State University · US

Funding

Production Center for Global Mapping of Regulatory ElementsU54HG004558 · NHGRI · YALE UNIVERSITY · PI SNYDER, MICHAEL P. · 2007 to 2011
$15.4M
Systems Analysis of Epigenomic Architecture in Cancer ProgressionU54CA217297 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JIN, VICTOR · 2017 to 2021
$9.3M
Omics analysis of three-dimensional transcriptional regulationR01GM114142 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JIN, VICTOR, LIN, SHILI · 2015 to 2024
$2.7M
Deciphering the molecular mechanisms of histone code recognition by ATAD2/BR01GM129338 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI FRIETZE, SETH E, GLASS, KAREN CHAMPAGNE · 2018 to 2022
$2.1M
Mechanism of Ikaros Tumor Suppression in progenitor B cell leukemiaR21CA209229 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRIETZE, SETH E, SCHJERVEN, HILDE · 2016 to 2017
$420k
Integration and epigenetic regulation of the HHV-6 genomeR21AI121528 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI FRIETZE, SETH E, KAUFER, BENEDIKT B. · 2016 to 2017
$400k
NCI NIH HHS R21 CA209229NCI NIH HHS U54 CA217297NHGRI NIH HHS U54 HG004558NIAID NIH HHS R21 AI121528NIGMS NIH HHS R01 GM114142NIGMS NIH HHS R01 GM129338
6 · The paper itself

Abstract

Distal regulatory elements influence the activity of gene promoters through chromatin looping. Chromosome conformation capture (3C) methods permit identification of chromatin contacts across different regions of the genome. However, due to limitations in the resolution of these methods, the detection of functional chromatin interactions remains a challenge. In the current study, we employ an integrated approach to define and characterize the functional chromatin contacts of human pancreatic cancer cells. We applied tethered chromatin capture to define classes of chromatin domains on a genome-wide scale. We identified three types of structural domains (topologically associated, boundary, and gap) and investigated the functional relationships of these domains with respect to chromatin state and gene expression. We uncovered six distinct sub-domains associated with epigenetic states. Interestingly, specific epigenetically active domains are sensitive to treatment with histone acetyltransferase (HAT) inhibitors and decrease in H3K27 acetylation levels. To examine whether the subdomains that change upon drug treatment are functionally linked to transcription factor regulation, we compared TCF7L2 chromatin binding and gene regulation to HAT inhibition. We identified a subset of coding RNA genes that together can stratify pancreatic cancer patients into distinct survival groups. Overall, this study describes a process to evaluate the functional features of chromosome architecture and reveals the impact of epigenetic inhibitors on chromosome architecture and identifies genes that may provide insight into disease outcome.

Indexed as

Gene Regulatory NetworksBenzoatesBridged Bicyclo Compounds, HeterocyclicCell Line, TumorChromatinChromatin Assembly and DisassemblyChromosome MappingEpigenesis, GeneticEpigenomicsGene Expression Regulation, NeoplasticHumansNitrobenzenesPancreatic NeoplasmsPyrazolesPyrazolonesPyrimidinones4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acidBenzoatesBridged Bicyclo Compounds, HeterocyclicChromatinICG 001NitrobenzenesPyrazolesPyrazolonesPyrimidinonesTCF7L2 protein, humanTranscription Factor 7-Like 2 Proteinaltered chromatin interactionchromatinhistone acetyltransferase (HAT)pancreatic ductal adenocarcinomaTCF7L2tethered chromatin capture (TCC)

Identifiers

PMID30548288
PMCPMC6476548
OpenAlexW2905484522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.